Tigecycline Market Size, Share, Growth and Industry analysis, By Type (Gram Positive Bacteria, Gram Negative Bacteria), By Application (Skin & Soft Tissue Infections, Complicated Intra-abdominal Infections, Community-acquired Bacterial Pneumonia) and Regional Forecast to 2034

• 

  Request a Free sample to learn more about this report

TIGECYCLINE MARKET OVERVIEW

The global tigecycline market size was valued at USD 2.772 billion in 2025 and is expected to reach USD 19.367 billion by 2034, growing at a compound annual growth rate (CAGR) of about 24.11% from 2025 to 2034.

The United States Tigecycline Market size is projected at USD 0.9572 Billion in 2025, the Europe Tigecycline Market size is projected at USD 0.8674 Billion in 2025, and the China Tigecycline Market size is projected at USD 0.5919 Billion in 2025.

Tigecycline is a kind of glycylcycline with a broad spectrum of activity that inhibits protein synthesis. By attaching to the bacterial 30S ribosomal subunit, tigecycline prevents aminoacyl-tRNA from interacting with the ribosome's A site, exhibiting bacteriostatic activity. Tigecycline has also been demonstrated to have bactericidal action against isolates of S. pneumoniae and L. pneumophila.  Under the trade name Tygacil, tigecycline is an antibiotic used to treat bacterial infections that are severe, including gonorrhoea, chlamydia, acne, and urinary tract infections. For the treatment of resistant gramme positive and gramme negative infections, tigecycline is utilised as an alternate drug, particularly in individuals with a history of penicillin allergy or toxicities associated with antibiotics. Moreover, tigecycline binds to bacterial ribosomes and stops them from making the necessary cell protein for bacterial growth and multiplication, but it does not really kill bacteria. For the treatment of bacterial infections, tigecycline is administered intravenously during a 30- to 60-minute period. The initial dose is 100 mg, followed by 50 mg every 12 hours. Moreover, a 14 to 15 day course of therapy is advised for severe skin infections, and a 7 to 14 day course is advised for treating community-acquired bacterial pneumonia.

TIGECYCLINE MARKET KEY FINDINGS

COVID-19 IMPACT

COVID-19 outbreak significantly disrupting the market growth

Globally, the COVID-19 pandemic has had an impact on a number of markets. Due to lockdown policies enacted by governments, pharmaceutical businesses are experiencing challenges like as regulatory modifications, changes in demand, delays in the licencing of generic medicines, disruptions in the supply chain, and product exporting restrictions. The market for tigecycline drugs worldwide is seeing negative growth.

LATEST TRENDS

Rising Use in Treatment Of Various Diseases Predicted To Boost Sales Prospects

The need for antibiotics will increase due to an increase in bacterial illnesses and the advent of germs that are resistant to antibiotics. Growing elderly populations and rising prevalence rates are predicted to boost sales prospects. The European Society of Clinical Microbiology and Infection recommends tigecycline as a viable salvage treatment for difficult and serious refractory Clostridium difficile infections. Tigecycline is also used to treat cancer patients and those with impaired immune systems. Moreover, tigecycline may be used to treat acute myeloid leukaemia. Every 12 hours, tigecycline is recommended for gradual intravenous infusion. Lower doses of tigecycline must be provided to patients with poor liver function. Those with poor renal function don't require any modifications.

• According to the U.S. FDA boxed warning, a pooled meta‑analysis of 13 Phase 3/4 trials showed an all‑cause mortality risk difference of 0.6% (4.0% vs. 3.0%) for tigecycline versus comparators; mortality reached 19.1% vs. 12.3% in ventilator‑associated pneumonia, and common adverse events such as nausea (26%) and vomiting (18%) further constrain routine use—pushing hospitals to position tigecycline as a last‑line rather than first‑line agent.

• According to the U.S. FDA (Drugs@FDA), beyond the originator NDA 021821 (Wyeth/Pfizer, approved June 15, 2005), at least two additional NDAs for tigecycline 50‑mg vials were filed under the 505(b)(2) pathway (e.g., NDA 205645 – Fresenius Kabi; NDA 211158 – Amneal), broadening potential supply. Simultaneously, according to the CDC (updated 2024), the U.S. still faces >2.8 million antimicrobial‑resistant infections and >35,000 deaths yearly, while WHO GLASS reports only ~37% of countries stably reporting AMR/AMC data.

Request a Free sample to learn more about this report

TIGECYCLINE MARKET SEGMENTATION

By Type Analysis

According to type, the market can be segmented into Gram Positive Bacteria, Gram Negative Bacteria

By Application Analysis

Based on application, the market can be divided into Skin & Soft Tissue Infections, Complicated Intra-abdominal Infections, Community-acquired Bacterial Pneumonia.

DRIVING FACTORS

Rising demand for Tigecycline For Medicines Purpose Will Fuel the Market Growth

The demand for tigecycline medicines on the market is being driven by the rising prevalence of gonorrhoea in the U.S. For instance, the 2017 data from the Centers for Disease Control and Prevention states that there were around 555,608 cases of gonorrhoea recorded in the United States. Hence, pharmaceutical firms are concentrating on releasing treatments for therapy for bacterial infections since they are becoming more common. As an illustration, in an effort to make Tygacil (Tigecycline) injection more affordable, Sandoz Inc. introduced the AP-rated generic version of the medication in 2017. These elements are anticipated to fuel the market for tigecycline products worldwide. Tigecycline functions as an antibiotic by treating a number of bacterial illnesses. Tigecycline is a first-generation glycylcycline that is injected into the vein. The prevalence of antibiotic resistance among several bacteria, including Acinetobacter baumannii, Staphylococcus aureus, and E. coli, was a major factor in the development of tigecycline. Due to structural changes made to tigecycline, a tetracycline derivative antibiotic, its therapeutic action has been expanded to encompass both Gram-positive and Gram-negative bacteria, including those that exhibit multi-drug resistance. Throughout the course of the projected period, the market is anticipated to rise due to the rising demand for tigecycline as an antibiotic.

• According to ECDC 2023 (reporting 2021 data), 6 of 44 countries (14%) reported ≥50% carbapenem resistance in Pseudomonas aeruginosa, and 17 of 44 countries (39%) reported ≥25% vancomycin resistance in Enterococcus faecium—numbers that keep clinicians looking for non‑β‑lactam, broad‑spectrum alternatives like tigecycline.

• According to the WHO 2024 antibacterial pipeline update, only 32 of the antibiotics in development target WHO bacterial priority pathogens, 12 are considered innovative, and just 4 hit at least one “critical” pathogen—creating a supply‑side gap that sustains market relevance for existing molecules such as tigecycline.

Rising Frequency, Chlamydia And Gonorrhoea Have A Significant Impact On Market Growth

Due to rising frequency, chlamydia and gonorrhoea have a significant impact in Europe. For instance, the National Health Service's 2018 report states that over 44,500 men and women under the age of 25 in England received gonorrhoea diagnoses in 2017. As a result, pharmaceutical firms are concentrating on new launches. to cure infectious disorders caused by bacteria. For instance, the European Medicines Agency authorised Accord Healthcare's request to sell tigecycline injection in February 2020 for the treatment of bacterial skin infections. Throughout the projected period, these factors are anticipated to fuel market expansion for tigecycline products globally.

RESTRAINING FACTORS

Adverse Effects Of The Antibiotic Tigecycline Restrict the Market Growth

The adverse effects of the antibiotic tigecycline include lower back discomfort, side pain, painful or difficult urination, vision or hearing issues, coughing or hoarseness, fever or chills, and headache. In addition, there are restrictions on the use of tigecycline due to an increase in mortality from ventilator- or hospital-acquired pneumonia.

Patients often like oral amoxicillin tablets over injections of tigecycline because they are more affordable than injections for treating bacterial infections. Amoxicillin 500 mg oral tablets cost US$ 23.99, whilst tigecycline injections cost US$ 79.22. These elements are anticipated to limit the market's expansion for tigecycline goods globally. The market's expansion may be hampered by high expenses. Also, it is projected that strict government rules on medicine release may constrain the worldwide tigecycline market.

• According to the U.S. FDA label, tigecycline showed a 0.6% higher adjusted mortality risk (4.0% vs. 3.0%; 95% CI 0.1–1.2) across 13 trials, with 19.1% vs. 12.3% mortality in ventilator‑associated pneumonia; nausea (26%) and vomiting (18%) are frequent adverse events, dampening frontline adoption

• According to the U.S. FDA label, tigecycline is not indicated for hospital‑acquired pneumonia (including VAP) or diabetic foot infection, and use in patients <18 years is not recommended—numerically excluding large pediatric and nosocomial pneumonia segments from routine use.

• Request a Free sample to learn more about this report

•  

TIGECYCLINE MARKET REGIONAL INSIGHTS

North America Region will Significantly Grow During Forecast Period

In 2019, it is anticipated that the North American region will continue to dominate the global tigecycline market. The United States is the primary geographical area. The key factor influencing this region's supremacy is the widespread knowledge of tigecycline therapy. The market for tigecycline products is divided into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa based on region. Since chlamydia trachoma is so common, tigecycline is becoming more and more popular in North America. For instance, the Centers for Disease Control and Prevention (CDC) For reasons of prevention, there were 1,598,354 instances of chlamydia trachomatis infection in the U.S. in 2016, compared to 497.3 cases per 100,000 in 2015. As a result, pharmaceutical firms are concentrating on the launch of new products to treat bacterial infectious diseases. A generic version of Pfizer's tygacil with single dosage vial, Tigecycline injection, was introduced by Fresenius Kabi in the United States in 2016.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• According to the U.S. FDA, Pfizer’s legacy Wyeth NDA 021821 (approved 15 June 2005) underpins tigecycline’s U.S. market entry; the FDA’s pooled analysis covered 3,788 tigecycline‑treated vs. 3,646 comparator‑treated patients with a 0.6% higher mortality risk.

• According to the WHO 2024 pipeline review, only 32 antibiotics in development target WHO priority pathogens, underscoring why large anti‑infective holders like Merck (with significant marketed carbapenem/BL‑BLI franchise, but no U.S. tigecycline NDA) face continued stewardship‑driven pressure to demonstrate true innovation in AMR, not legacy expansion.

List of Top Tigecycline Companies

• Sanofi
• Amgen
• Jiagsu Aosaikang Pharmaceutical
• Progen Nutraceuticals
• Novartis
• Johnson & Johnson
• HICIN Pharma
• Roche Holdings
• Abbott Laboratories
• Hisun Pharma
• Merck
• Lifecare Innovations
• Hansoh Pharma
• Astrazeneca
• Pfizer

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.